In this single-center retrospective study of metastatic uveal melanoma, dual checkpoint blockade with ipilimumab plus nivolumab achieved higher response and disease control rates than PD-1 inhibitor monotherapy, albeit with substantially greater toxicity. The gene discussed is PDCD1; the disease is uveal melanoma.